Status: Recruiting
JUR-003 in Adult Patients With Metastatic Prostate Cancer
JUR-003-ONC-101 is a first-in-human Phase 1a/1b open-label, multicenter study to evaluate the safety, tolerability, PK, pharmacodynamics, and preliminary anti-tumor activity of JUR-003 in patients with prostate cancer. This study is divided into 2 parts: Phase-1a Dose Escalation (Part 1), and Phase-1b Dose Expansion (Part 2). In each part, patients who meet specific eligibility criteria will be enrolled.
Participants needed: 210
Trial details
Phase: Phase 1Age: 18+Biological sex: MaleType: InterventionalSponsor: Juri Biosciences, Inc.Updated: Oct 2, 2026Locations: 3
Eligibility criteria
Must be ≥18 years of age at the time the informed consent form (ICF) is signed. [+4]
Has a diagnosis of immunodeficiency. [+10]